# Xuefeng Xia

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xuefeng-xia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,567 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 27 |
| i10-index | 40 |
| Last Known Institution | BGI Group (China) |
| OpenAlex ID | https://openalex.org/A5102942545 |
| ORCID iD | 0000-0002-6390-1709 |
| Works | 215 |

## Researcher papers

- [Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer](https://scholariq.org/papers/local-mutational-diversity-drives-intratumoral-immune-heterogeneity-in-non-small/)
- [Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer](https://scholariq.org/papers/safety-and-feasibility-of-crispr-edited-t-cells-in-patients-with-refractory-non/)
- [Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients](https://scholariq.org/papers/pan-cancer-circulating-tumor-dna-detection-in-over-10-000-chinese-patients/)
- [Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer](https://scholariq.org/papers/circulating-tumor-dna-analysis-depicts-subclonal-architecture-and-genomic/)
- [Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer](https://scholariq.org/papers/deep-sequencing-of-circulating-tumor-dna-detects-molecular-residual-disease-and/)
- [The feasibility of using mutation detection in ctDNA to assess tumor dynamics](https://scholariq.org/papers/the-feasibility-of-using-mutation-detection-in-ctdna-to-assess-tumor-dynamics/)
- [Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer](https://scholariq.org/papers/circulating-tumor-dna-analyses-predict-progressive-disease-and-indicate/)
- [ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy](https://scholariq.org/papers/ctdna-dynamics-a-novel-indicator-to-track-resistance-in-metastatic-breast-cancer/)
- [Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer](https://scholariq.org/papers/assessing-tumor-heterogeneity-using-ctdna-to-predict-and-monitor-therapeutic/)
- [Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance](https://scholariq.org/papers/identifying-circulating-tumor-dna-mutation-profiles-in-metastatic-breast-cancer/)
- [P59.13 The Prediction Performance of TP53 / RB1 Co-Mutation on Small-Cell Lung Cancer Transformation in Patients With Non-Small Cell Lung Cancer](https://scholariq.org/papers/p59-13-the-prediction-performance-of-tp53-rb1-co-mutation-on-small-cell-lung/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)

## Researcher university

- [BGI Group (China)](https://scholariq.org/institutions/bgi-group-china/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.